Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥3,925.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥38.15B
Enterprise Value¥30.67B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)37.1
Beta1.18
Next Earnings
Sep 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)25.93
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-94.5
Revenue Forecast (FY)¥451.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and a large equity base provide durable financial flexibility, reducing refinancing and solvency risk. This conservatism supports strategic optionality — R&D, partnerships, or M&A — and cushions the company through revenue cycles, a lasting strength over the next 2–6 months.
FY2025 Profitability TurnaroundA clear operating inflection in FY2025 with meaningful revenue growth and restored profitability signals that core commercial or operational constraints were addressed. If execution continues, the structural shift to positive margins supports reinvestment and makes cash generative outcomes more likely over the medium term.
Improved Cash GenerationConversion of profits into roughly equal free cash flow demonstrates improving cash quality and lowers external funding needs. Sustainable positive FCF enhances capacity for capex, clinical spending, or distribution expansion, underpinning longer-term viability if trends persist beyond one fiscal year.
Bears Say
Multi-year Loss HistoryA prior multi-year loss and cash-burn record indicates structural execution risk and earnings volatility. Even with a FY2025 recovery, historical negative periods mean forecasts must assume possible reversals, higher sensitivity to operational setbacks, and continued vigilance on sustaining profitable execution.
Inconsistent Gross Profit ReportingIrregular gross profit disclosure and a reported zero gross profit year undermine confidence in margin comparability and cost structure transparency. This complicates durable margin forecasting, reduces model reliability, and raises execution uncertainty for pricing or manufacturing improvements.
Small Workforce / Key-person RiskA very small employee base raises operational and scalability risks: limited bandwidth for commercialization, R&D, and regulatory processes, and concentrated key-person dependencies. Over 2–6 months, this can constrain execution speed and amplify risks if attrition or capacity issues occur.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥3925.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥38.15B.
When is Heartseed, Inc.’s upcoming earnings report date?
Heartseed, Inc.’s upcoming earnings report date is Sep 10, 2026 which is in 70 days.
How were Heartseed, Inc.’s earnings last quarter?
Heartseed, Inc. released its earnings results on Jun 11, 2026. The company reported -¥2.54 earnings per share for the quarter, missing the consensus estimate of N/A by -¥2.54.
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,874,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Heartseed, Inc. reported an EPS of -¥2.54 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.149%.
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Headquartered in Tokyo, Japan, Heartseed, Inc. was established on November 30, 2015, by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa, and Yutaro Kasai. The company specializes in the development and advancement of cardiac regenerative medicine.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―
Options Prices
Currently, No data available
---